New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Novavax, Inc.

NVAX

Healthcare Biotechnology

Novavax, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 billion, up 64.7% from fiscal 2024.

Revenue
−3.05%
EPS
n/m
Free cash flow
n/m
Total debt
+19.3%

Quarter to September 2026, against a year earlier

7.73 0.00 0.00%
Market cap
$1.3B
P/E
n/m
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
5/9
ROIC
0.00%
Net debt / EBITDA
−1.0×
Payout ratio
—

Ratios over time Q4 FY25 to Q3 FY26

Returns on capital

ROIC was 0.00% in Q3 FY26, the highest of these four quarters. ROE, at 41.1%, is far above it because equity is small against the capital the business uses.

ROEROIC
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
ROE−117.2%79.7%323.7%41.1%
ROIC0.0%0.0%0.0%0.0%

Debt

Net debt is 11.64× a year’s EBITDA.

Net debt / EBITDA
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Net debt / EBITDA−25.8×40.2×8.2×11.6×

Cash cycle, in days

Customers pay in 44 days, inventory is held 75 days and suppliers are paid in 101. Cash is tied up for 18 days between paying for goods and being paid.

Cash cycleDays to pay suppliersDays to be paid
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Cash cycle−31−5−3718
Days to pay suppliers1236695101
Days to be paid35141744

Per share, from Q4 FY25

Since Q4 FY25, per share: revenue has fallen 64.0%.

Revenue
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Revenue1.0×0.5×0.4×0.4×
Sep '26 Jun '26 Mar '26 Dec '25 Older periods
P/E ratio
0.00 0.00 0.00 2.45

+8 more quarters

P/S ratio
4.33 3.75 2.23 0.97
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(18.92) (21.29) (40.99) (27.58)
P/B ratio
0.00 0.00 0.00 0.00
Price to Tangible BV
0.00 0.00 0.00 0.00
EV/Sales
3.53 2.72 1.39 0.52
EV/EBITDA
0.00 0.00 0.00 1.23
EV/Operating CF
(6.09) (30.46) (9.08) (2.41)
EV/FCF
(5.93) (25.52) (8.43) (2.34)
Quick Ratio
2.04 2.23 2.38 1.85
Current Ratio
2.15 2.33 2.48 2.13
Net Debt/EBITDA
11.64 8.22 40.22 (25.82)
Debt/Assets
33.06% 30.68% 28.08% 20.94%
Debt/Equity
(1.35) (1.54) (2.02) (1.93)
Asset Turnover
0.40 0.36 0.51 0.82
Operating CF/Net income
3.00 1.36 3.42 (2.25)
Capex/Depreciation
(0.34) (0.19) (0.41) (0.31)
Interest Coverage
(5.79) (9.65) (3.15) 2.44
Research and Development Expense of Revenue
76.79% 124.68% 68.43% 51.57%
Selling, General and Administrative Expense of Revenue
34.62% 47.03% 20.63% 23.19%
Intangible Assets out of Total Assets
0.13 0.12 0.11 0.10
Share Based Compensation of Revenue
11.65% 14.27% 5.54% 5.41%
Graham Net Nets
(0.22) (0.24) (0.25) (0.30)
Graham Number
3.69 6.30 3.28 0.00
Earnings Yield
(4.26%) (16.14%) (6.63%) 40.77%
Free Cash Flow Yield
(13.75%) (2.84%) (7.42%) (23.15%)
Revenue per Share
0.41 0.34 0.85 0.91
Operating CF per Share
(0.57) (0.44) (0.20) (0.24)
Capex per Share
(0.01) 0.00 (0.01) (0.01)
Free Cash Flow per Share
(0.58) (0.45) (0.21) (0.25)
Cash per Share
3.77 4.37 4.84 4.60
Shareholders Equity per Share
(1.31) (1.16) (0.89) (0.79)
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
(1.31) (1.16) (0.89) (0.79)
Free Cash Flow
(95.26) (73.39) (33.69) (41.07)
Working Capital
378.11 440.52 508.36 518.33
Capital Expenditures
(1.02) (0.59) (1.27) (1.59)
Net Current Asset Value
(396.90) (375.18) (337.11) (325.99)
EV/EBIT
0.00 0.00 0.00 1.30
Capex to Sales
0.01 0.01 0.01 0.01
Price to Operating Income
0.00 0.00 0.00 2.40
Other line items
Average Receivables
41.67 122.57 33.91 107.37
Average Payables
20.09 36.77 25.13 33.08
Average Inventory
16.01 10.12 10.86 10.15
Average Assets
1,033.95 1,146.06 1,168.08 1,368.47
Average Common Equity
(186.76) (76.54) (110.20) (375.80)

Fold the line items

Columns are period end dates · fundamentals updated Nov 18, 2026